What You Should Know:
- Evogene Ltd. a leading computational biology company targeting to revolutionize life-science product development across multiple market segments, and Verb Biotics LLC., a microbiome health ingredient company whose mission is to improve human health, entered into a collaboration agreement that will focus on the development of new strains of probiotic bacteria, which produce a highly sustainable quantity of microbial metabolites that improve human health and vitality.
- The collaboration will focus on identifying and enhancing the currently unknown genetic pathways in microbes that support the production of novel metabolites, using Evogene’s MicroBoost AI tech-engine and Verb Biotics’ extensive accumulated knowledge in the field of the microbiome.
Evogene and Verb Biotics Lead the Way in Microbiome Innovation
The probiotics market is projected to double to $114 billion by 2031, driven by growing awareness of the microbiome’s role in health. Evogene and Verb Biotics are collaborating to capitalize on this trend, combining Evogene’s MicroBoost AI technology for bacterial product development with Verb Biotics’ expertise in microbial strain genomes, aiming to produce vital microbial metabolites for human health. This partnership leverages the expanding importance of global microbiome research to drive innovation in microbiome products for a healthier lifestyle.
“Partnering with Evogene equips Verb Biotics with a powerful edge to revolutionize microbiome-driven health solutions. By leveraging Evogene’s technology, we further streamline and de-risk our innovation pathway, prioritizing function-first approaches for optimal microbiome health”, says Noah Zimmerman, CTO at Verb Biotics.
